Pathology: mML - L1 - all population; mML - L2 - all population; mML - NA - all population;
| mML - L1 - all population | mML - L2 - all population | mML - NA - all population | |||||||||
| A3671009, 2013 | Ascierto (ipi 10 vs 3 mg/kg), 2017 | CA184-004, 2011 | MDX010 Ipi vs gp100, 2010 | MDX010 Ipi plus gp100 vs gp100, 2010 | MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 | CA184-024, 2011 | E1609 (ipi10), 2020 | EORTC 18071, 2015 | E1609 (ipi3), 2020 | ||
| Ipilimumab (10 mg/kg) | 4 | T1 | T1 | T1 | T1 | ||||||
| ipilimumab alone | 2 | T0 | T0 | T1 | T0 | T1 | |||||
| ipilimumab plus gp100 | 2 | T1 | T1 | ||||||||
| tremelimumab | 1 | T1 | |||||||||
| ipilimumab plus SoC | 1 | T1 | |||||||||
| interferon alpha | 0 | T0 | T0 | ||||||||
| placebo | 0 | T0 | |||||||||
| Standard of Care (SoC) | 0 | T0 | |||||||||
| placebo plus SoC | 0 | T0 | |||||||||
| gp100 | 0 | T0 | T0 | ||||||||